Reischig Tomas, Kacer Martin
Department of Internal Medicine I, Charles University Medical School and Teaching Hospital, Alej Svobody 80, 304 60 Pilsen, Czech Republic.
Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):771-9. doi: 10.1586/14737167.2014.965157. Epub 2014 Sep 25.
Prevention of cytomegalovirus infection using antiviral prophylaxis or the pre-emptive therapy approach is an integral part of management of patients after solid organ transplantation. Regarding renal transplantation, valacyclovir is currently the only antiviral agent recommended for prophylaxis as an alternative to valganciclovir. This review article discusses studies documenting the efficacy and safety of valacyclovir prophylaxis as well as those comparing valacyclovir with other prophylactic regimens or with pre-emptive therapy. Also addressed are the economic aspects supporting the cost-effectiveness of valacyclovir prophylaxis and demonstrating lower costs compared with other cytomegalovirus preventive strategies.
使用抗病毒预防或抢先治疗方法预防巨细胞病毒感染是实体器官移植后患者管理的一个组成部分。对于肾移植，目前伐昔洛韦是唯一推荐用于预防的抗病毒药物，可作为缬更昔洛韦的替代药物。这篇综述文章讨论了记录伐昔洛韦预防疗效和安全性的研究，以及将伐昔洛韦与其他预防方案或抢先治疗进行比较的研究。还讨论了支持伐昔洛韦预防成本效益并证明其成本低于其他巨细胞病毒预防策略的经济方面。
